Product Description

Fem-Dophilus® maintains and balances vaginal microbiome and
urinary tract health* with GR-1® & RC-14® strains. Over 30 years of
clinical research supports the effectiveness of the 2 patented probiotic
bacterial strains in Fem-Dophilus®. Probiotic for Women with 30+ Years of
Clinical Research. Supports Vaginal and Urinary Tract Health*. Shelf-Stable
Version of Fem-Dophilus: No Refrigeration Necessary. Clinically-Documented
Benefits. More Than 20 Studies Demonstrating Safety and Efficacy. With 2
patented strains: Lacticaseibacillus rhamnosus GR-1® and Limosilactobacillus
reuteri RC-14®. These beneficial strains populate the vaginal tract with
healthy bacteria to balance the vaginal microbiome and help maintain a healthy
vaginal and urinary tract.* These two strains are the most clinically published
strains for vaginal health worldwide**, and were carefully selected due to
their effectiveness in these studies.* A special manufacturing process protects
the probiotic strains in Fem-Dophilus® from stomach acid, enhances probiotic
bacterial survival to the lower intestine, and into the vaginal tract.*.
Package contains a smaller, Activ-Vial™ moisture-controlled desiccant bottle
for better stability of probiotic bacteria. In one randomized clinical trial,
60% of women studied had healthy vaginal flora after 28 days of use at 0.8
billion CFU per day of a probiotic (formulated with L. rhamnosus, GR-1® and L.
reuteri, RC-14®) compared to 40% before supplementation. Whereas in the control
group (taking 10 billion CFU of common strain, L. rhamnosus GG) there was no
improvement in the percentage of women with healthy vaginal flora. .